Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan-Herndon-Dudley Syndrome
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Mutations in the thyroid hormone transporter SLC16A2 (MCT8) cause the Allan–Herndon–Dudley Syndrome (AHDS), characterized by severe psychomotor retardation and peripheral thyrotoxicosis. Here, we report three newly identified AHDS patients. Previously documented mutations were identified in probands 1 (p.R271H) and 2 (p.G564R), resulting in a severe clinical phenotype. A novel mutation (p.G564E) was identified in proband 3, affecting the same Gly564 residue, but resulting in a relatively mild clinical phenotype. Functional analysis in transiently transfected COS-1 and JEG-3 cells showed a near-complete inactivation of TH transport for p.G564R, whereas considerable cell-type-dependent residual transport activity was observed for p.G564E. Both mutants showed a strong decrease in protein expression levels, but differentially affected Vmax and Km values of T3 transport. Our findings illustrate that different mutations affecting the same residue may have a differential impact on SLC16A2 transporter function, which translates into differences in severity of the clinical phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter
Friesema, E. C. H., Ganguly, S., Abdalla, A., Fox, J. E. M., Halestrap, A. P., & Visser, T. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300909200 · Cited by 725 · cited 2×
“SLC16A2 (monocarboxylate transporter 8; MCT8; MIM# 300095) is the most specific TH transporter identified to date and is crucial for TH transport across the blood–brain barrier and into neuronal cells [Friesema et al., 2003; Ceballos et al., 2009; Heuer and Visser, 2009; Wirth et al., 2009; Kinne et al., 2010].”
BackgroundSelf-citationFriesema, E. C., Grueters, A., Biebermann, H., Krude, H., von Moers, A., Reeser, M., Barrett, T. G., Mancilla, E. E., Svensson, J., Kester, M. H., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17226-7 · Cited by 709 · cited 4×
“The neurocognitive phenotype comprises moderate–severe intellectual disability, axial hypotonia, dystonia, and progressive spasticity, leading to poor head control, inability to sit, stand, or walk independently, and an impaired or absent speech development [Dumitrescu et al., 2004; Friesema et al., 2004].”
BackgroundSelf-citationDumitrescu, A. M., Liao, X.-H., Best, T. B., Brockmann, K., & Refetoff, S. (2004) · The American Journal of Human Genetics · doi:10.1086/380999 · Cited by 706 · cited 4×
“The neurocognitive phenotype comprises moderate–severe intellectual disability, axial hypotonia, dystonia, and progressive spasticity, leading to poor head control, inability to sit, stand, or walk independently, and an impaired or absent speech development [Dumitrescu et al., 2004; Friesema et al., 2004].”
BackgroundInfluentialHennemann, G., Docter, R., Friesema, E. C. H., de Jong, M., Krenning, E. P., & Visser, T. J. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0435 · Cited by 394 · cited 1×
“Since the metabolism and action of TH occurs intracellularly, transporter proteins are required to facilitate the transport of TH across the cell membrane [Hennemann et al., 2001].”
BackgroundSelf-citationCeballos, A., Belinchon, M. M., Sanchez-Mendoza, E., Grijota-Martinez, C., Dumitrescu, A. M., Refetoff, S., Morte, B., & Bernal, J. (2009) · Endocrinology · doi:10.1210/en.2008-1616 · Cited by 173 · cited 2×
“SLC16A2 (monocarboxylate transporter 8; MCT8; MIM# 300095) is the most specific TH transporter identified to date and is crucial for TH transport across the blood–brain barrier and into neuronal cells [Friesema et al., 2003; Ceballos et al., 2009; Heuer and Visser, 2009; Wirth et al., 2009; Kinne et al., 2010].”
BackgroundLópez-Espíndola, D., Morales-Bastos, C., Grijota-Martínez, C., Liao, X.-H., Lev, D., Sugo, E., Verge, C. F., Refetoff, S., Bernal, J., & Guadaño-Ferraz, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2162 · Cited by 155
Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency
Verge, C. F., Konrad, D., Cohen, M., Di Cosmo, C., Dumitrescu, A. M., Marcinkowski, T., Hameed, S., Hamilton, J., Weiss, R. E., & Refetoff, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2556 · Cited by 134 · cited 1×
“Beneficial effects on TFTs have also been observed in AHDS patients treated with the T3 analogue DITPA [Verge et al., 2012].”
BackgroundTrajkovic-Arsic, M., Müller, J., Darras, V. M., Groba, C., Lee, S., Weih, D., Bauer, K., Visser, T. J., & Heuer, H. (2010) · Endocrinology · doi:10.1210/en.2010-0593 · Cited by 87
Self-citationMutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution
Kersseboom, S., Kremers, G.-J., Friesema, E. C. H., Visser, W. E., Klootwijk, W., Peeters, R. P., & Visser, T. J. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1356 · Cited by 45
Self-citation
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease
Felmlee, M. A., Jones, R. S., Rodriguez-Cruz, V., Follman, K. E., & Morris, M. E. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018762 · Cited by 467
Groeneweg, S., van Geest, F. S., Peeters, R. P., Heuer, H., & Visser, W. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz008 · Cited by 216
Self-citationDisorder of thyroid hormone transport into the tissues
Groeneweg, S., Visser, W. E., & Visser, T. J. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.05.001 · Cited by 75
Self-citationSchmidt, R. L., LoPresti, J. S., McDermott, M. T., Zick, S. M., & Straseski, J. A. (2018) · Thyroid · doi:10.1089/thy.2017.0645 · Cited by 23
“There are also some rare conditions such as consumptive hypothyroidism, MCT8 mutations, and SBP2 mutations where rT3 measurements can be helpful in characterizing the phenotype and the underlying mechanism of disease (23,29,30).”
Metadata
- Authors
- Novara, F., Groeneweg, S., Freri, E., Estienne, M., Reho, P., Matricardi, S., Castellotti, B., Visser, W. E., Zuffardi, O., & Visser, T. J.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2017-01-05
- Volume
- 38
- Issue
- 3
- Pages
- 260-264
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2547403640
- Cited by
- 38
- References
- 9
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan-Herndon-Dudley Syndrome. https://app.cochat.ai/papers/10.1002/humu.23140
- The paper
- Novara, F., Groeneweg, S., Freri, E., Estienne, M., Reho, P., Matricardi, S., Castellotti, B., Visser, W. E., Zuffardi, O., & Visser, T. J. (2017). Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan-Herndon-Dudley Syndrome. Human Mutation. https://doi.org/10.1002/humu.23140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.